Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Nacubactam in Renal Impairment and Hemodialysis
NCT02975388Phase 1Completed
- Sponsor
- Roche
- Start
- Dec 2016
- Primary completion
- Jul 2017
- Modality
- Multivalent & Scaffold-Based Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of Nacubactam in gram-negative bacterial infections (5 arms), sponsored by Roche. Primary endpoints: Total Body Clearance at 24 hours, Volume of Distribution of the Central Compartment at 24 hours and 5 more. Started Dec 2016; status: completed.
02
Drugs
Nacubactam
03
Conditions
gram-negative bacterial infections
Beyond the preview
Go deeper on NCT02975388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02975388.